LANCET ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2019-01-01 sunliang

这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表:
是周彩存

153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存

596 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2017-07-16 gu_8183

谁能预测明年会有多少分?

754 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2017-02-02 1e1fbc2fm67(暂无匿称)

是周彩存littlestarstar 2016-10-01 发表::
请问是不是接收后才要system review的？一开始投稿并不需要吧？

littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？

504 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2016-10-01 littlestarstar

请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表::
研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。

丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。

435 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2016-08-19 ms7269483029162029

this is a reply：
thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority.
although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future.
haha.

121 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2016-04-05 心流

审稿速度:1.0 | 投稿命中率:5.0
经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。
Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority.
Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future.

443 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2015-10-19 ruipinsu

是不是约稿为主啊

411 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2014-07-31 henrypoor

谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~

499 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2014-07-30 henrypoor

今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！

516 0

[GetPortalCommentsPageByObjectIdResponse(id=565039, encodeId=02e1565039a0, content=这个杂志收基础的文章吗？153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, beContent=153****5167(暂无匿称) 2017-02-02 14:14:00 发表: 是周彩存, objectType=tool_impact_factor, channel=null, level=null, likeNumber=596, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/15/af911bdd940ac5430dfecaae1ba3bfff.jpg, createdBy=75e41936661, createdName=sunliang, createdTime=Tue Jan 01 00:00:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544512, encodeId=94e0544512d7, content=谁能预测明年会有多少分?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=754, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=gu_8183, createdTime=Sun Jul 16 19:15:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=532396, encodeId=633e53239677, content=是周彩存littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, beContent=littlestarstar 2016-10-01 发表:: 请问是不是接收后才要system review的？一开始投稿并不需要吧？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=504, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f452014981, createdName=1e1fbc2fm67(暂无匿称), createdTime=Thu Feb 02 14:14:00 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=527822, encodeId=cc3952e82213, content=请问是不是接收后才要system review的？一开始投稿并不需要吧？丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, beContent=丁丁 2014-07-30 发表:: 研究方向：肿瘤;NSCLC;乳腺癌接收率：约25% 审稿时间：约1个月 SCI(2013)：24.725楼上投稿，秒拒，可能是研究根本不合适。Lancet Oncology，国内发得多了，吴一龙教授，周彩纯教授，滕皋军教授，他们发了好多，尤其是吴一龙教授和周彩纯教授，几乎成为Lancet Oncology专业户了。一般来说，首先是RCT，但是可以是小规模的（即phase 2），这是可以的。另外，研究应该是很新的话题，如NSCLC，前几年研究EGFR突变，现在呢，一定要做ALK或ROS1之类，另外，研究的传承至关重要，因为发表前，都要附一个system review才可以，你要说明，为什么要开展这个研究，而不是无缘无故做的。我知道medsci协助国内好多大牛发了这个刊物。只要研究合适，似乎并不是这么恐怖的刊物。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=435, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb7d1609316, createdName=littlestarstar, createdTime=Sat Oct 01 20:56:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=833212, encodeId=519a833212d1, content=this is a reply： thank you for your recent submission to the lancet oncology. we have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. although this decision has not been a positive one, i thank you for your interest in the journal and hope it does not deter you from considering us again in the future. haha. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48345414140, createdName=ms7269483029162029, createdTime=Fri Aug 19 11:24:14 CST 2016, time=2016-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=521028, encodeId=224f52102832, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：速度相当得快啊，下午投完稿，晚上就收到编辑的邮件，无理由的秒据，伤感。。。。。。。。 Thank you for your recent submission to The Lancet Oncology. We have now had time to consider your manuscript and unfortunately, on this occasion, we have decided not to pursue it on the grounds of editorial priority. Although this decision has not been a positive one, I thank you for your interest in the journal and hope it does not deter you from considering us again in the future., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=443, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=738d1704566, createdName=心流, createdTime=Tue Apr 05 19:27:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516136, encodeId=59e4516136d4, content=是不是约稿为主啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f21293613, createdName=ruipinsu, createdTime=Mon Oct 19 20:21:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504793, encodeId=69f3504e933e, content=谢谢楼上的建议啦！课题组之前发了两篇这杂志的文章。基本都是类似的东西，那应该还是会送外审的。还正如您所说，确实是关于NSCLC的。文章修改阶段已经拖了蛮久，就希望能够尽早知道答案。内心忐忑啊~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Thu Jul 31 08:18:00 CST 2014, time=2014-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504734, encodeId=a77b504e3441, content=今天投了一篇，要么就秒拒，要不就赶紧送外审了吧，跪求！！！求祝福！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=516, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c35a106652, createdName=henrypoor, createdTime=Wed Jul 30 17:57:00 CST 2014, time=2014-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=483139, encodeId=9b3a48313981, content=偏重的研究方向：肿瘤;癌症;, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=791, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jul 03 11:23:00 CST 2011, time=2011-07-03, status=1, ipAttribution=)]

2011-07-03 匿名用户

偏重的研究方向：肿瘤;癌症;

791 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务